Companies:
49,943
Total Market Cap:
142461750629821.41
Global Rank
#24962
Country Rank
#83
Market Cap
99.14 M
Price
0.218
Change (%)
1.91%
Volume
223,907
BioPorto A/S's latest marketcap:
99.14 M
As of 07/26/2025, BioPorto A/S's market capitalization has reached $99.14 M. According to our data, BioPorto A/S is the 24962th most valuable company globally by market capitalization. Market capitalization, commonly referred to as market cap, represents the total market value of all outstanding shares of a publicly traded company and is often used as a measure of company value.
| Market Cap | 99.14 M |
| Revenue (ttm) | 5.42 M |
| Net Income (ttm) | -12,924,074.13 |
| Shares Out | 454.66 M |
| EPS (ttm) | -0.03 |
| Forward PE | 0.00 |
| Ex-Dividend Date | n/a |
| Earnings Date | 08/15/2025 |
Market Cap Chart
Data Updated: 07/26/2025
BioPorto A/S's yearly market capitalization.
BioPorto A/S has seen its market value grow from kr199.19 M to kr630.16 M since 2014, representing a total increase of 216.37% and an annual compound growth rate (CAGR) of 11.51%.
| Date | Market Cap(kr) | Market Cap(USD) | Change (%) | Global Rank |
|---|---|---|---|---|
| 07/26/2025 | kr630.16 M | $99.14 M | -5.38% | 24962 |
| 12/30/2024 | kr665.97 M | $92.1 M | -16.07% | 23781 |
| 12/29/2023 | kr793.48 M | $117.45 M | 2.41% | 22034 |
| 12/30/2022 | kr774.78 M | $111.18 M | 17.16% | 21592 |
| 12/30/2021 | kr661.32 M | $101.08 M | -38.59% | 23050 |
| 12/30/2020 | kr1.08 B | $176.29 M | 110.11% | 17434 |
| 12/30/2019 | kr512.55 M | $76.68 M | -11.61% | 19516 |
| 12/28/2018 | kr579.86 M | $88.78 M | 12.66% | 17880 |
| 12/29/2017 | kr514.69 M | $82.56 M | 72.02% | 18958 |
| 12/30/2016 | kr299.21 M | $42.34 M | -52.1% | 20148 |
Company Profile
About BioPorto A/S
BioPorto A/S is an in-vitro diagnostics company specializing in biomarker tools and antibodies for clinical research. The company operates globally, serving markets in Europe, North America, Asia, and beyond.
Key Offerings
- Neutrophil Gelatinase-Associated Lipocalin (NGAL) Test: A quantitative particle-enhanced turbidimetric immunoassay designed for automated clinical chemistry analyzers.
- Monoclonal Antibodies: Used in scientific, pharmaceutical, and clinical research applications.
- ELISA Kits: Enzyme-linked immunosorbent assay kits for diagnostic and research purposes.
- Generic Rapid Assay Device: Custom lateral flow assays for versatile diagnostic solutions.
Company Background
Founded in 1917, BioPorto A/S is headquartered in Hellerup, Denmark, with a long-standing reputation in the diagnostics and research industry.
Frequently Asked Questions
-
What is BioPorto A/S's (CPH-BIOPOR) current market cap?As of 07/26/2025, BioPorto A/S (including the parent company, if applicable) has an estimated market capitalization of $99.14 M USD. This figure represents the total market value of its outstanding shares, including different share classes. Please note that market capitalization fluctuates based on market conditions, and the actual valuation may differ from the latest estimate.
-
Where does BioPorto A/S (CPH-BIOPOR) rank globally by market cap?BioPorto A/S global market capitalization ranking is approximately 24962 as of 07/26/2025. This ranking is relative to all publicly traded companies worldwide and can fluctuate based on market dynamics and the performance of other companies. You can refer to our Global companies market cap ranking for the most up-to-date ranking.